Is Titan Biotech overvalued or undervalued?

As of 4 July 2025, Titan Biotech's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a PE ratio of 17.57, an EV to EBITDA of 14.77, and a Price to Book Value of 2.47. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Titan Biotech's PE ratio is notably lower than Solar Industries, which has a PE of 125.92, and significantly higher than Godrej Industries, which is considered attractive with a PE of 40.05. The overall peer comparison shows that Titan Biotech is in a very expensive category alongside companies like Gujarat Fluoroch and Deepak Nitrite, both of which also exhibit high valuation metrics. Despite a strong historical performance over the long term, recent returns indicate a decline, with a year-to-date drop of 37.50% compared to a 6.77% gain in the Sensex.